Choreo LLC Sells 1,667 Shares of AstraZeneca PLC (NASDAQ:AZN)

Choreo LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.2% during the fourth quarter, HoldingsChannel reports. The fund owned 50,375 shares of the company’s stock after selling 1,667 shares during the quarter. Choreo LLC’s holdings in AstraZeneca were worth $3,303,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of AZN. Bank of Montreal Can boosted its stake in shares of AstraZeneca by 109.6% in the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after purchasing an additional 1,522,715 shares during the last quarter. Erste Asset Management GmbH bought a new stake in shares of AstraZeneca in the 3rd quarter valued at $72,437,000. Manning & Napier Advisors LLC lifted its position in shares of AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock valued at $245,407,000 after acquiring an additional 564,297 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after acquiring an additional 524,175 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Performance

AZN opened at $72.36 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company’s fifty day moving average price is $67.27 and its two-hundred day moving average price is $73.70. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a market cap of $224.39 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. On average, analysts expect that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.